Health ProductsPublic Communication

Apo-Clindamycin, Clindamycine-150 and Clindamycine-300 (clindamycin hydrochloride) - Presence of Trace Amounts of Quetiapine Fumarate in the Capsules - For the Public

· Published by Health Canada · Official notice

Details

Alert type: Public Communication
Category: Drugs
Issue: Contamination
Audience: General Public
Department: Health Canada
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Details

This is duplicated text of a letter from Apotex Inc. and Pro-Doc Limitée. Contact the company for a copy of any references, attachments or enclosures.

Notice about Health Canada advisories

PUBLIC COMMUNICATION - Health Canada Endorsed Important Safety Information on APO-CLINDAMYCIN, CLINDAMYCINE-150, and CLINDAMYCINE-300

May 25, 2013

Subject:      Important safety information for patients who are prescribed APO-CLINDAMYCIN, CLINDAMYCINE-150 and CLINDAMYCINE-300 capsules and who have a history of allergy to quetiapine.

Apotex Inc. and Pro Doc Ltée, in consultation with Health Canada, wishes to advise you that their supplier of clindamycin hydrochloride may have inadvertently caused trace amounts of the anti-psychotic drug quetiapine to be present in the clindamycin raw material. Exposure to quetiapine in patients known to be allergic should be avoided.

APO-CLINDAMYCIN, CLINDAMYCINE-150 and CLINDAMYCINE-300 contain clindamycin hydrochloride, an antibiotic, which is used to treat many infections. Some examples of uses of clindamycin are to treat infections in patients who are allergic to penicillin, in cases when other antibiotics are not effective, before dental, oral and upper respiratory tract surgery, and for pneumonia in AIDS patients.

Clindamycin is considered a medically necessary drug. As Apotex and Pro Doc currently supply about 75% of the Canadian market needs for clindamycin, taking steps to ensure continued patient access to this medication is of utmost importance. As a result, this advisory is only directed to the specific group of patients identified in the bullets below.

  • Trace amounts of the drug quetiapine may be present in APO-Clindamycin, Clindamycine-150 and Clindamycine-300
  • If you are allergic to quetiapine do not take APO-Clindamycin, Clindamycine-150 and Clindamycine-300. If you are allergic to quetiapine and presently taking APO-Clindamycin, Clindamycine-150 and Clindamycine-300 please contact your pharmacist immediately
  • If you are unsure if you are allergic to quetiapine please contact your health care professional to find out

Background

An inspection of a Pharmaceutical Factory in China was conducted by the European Directorate for the Quality of Medicines and Healthcare (EDQM) recently.  During this inspection, a concern was identified about possible contamination of clindamycin with quetiapine.  This contamination may have resulted from trace amounts of quetiapine on common equipment.

Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of serious allergic reactions or other serious or unexpected adverse reactions in patients receiving APO-Clindamycin should be reported to Apotex Inc. or Health Canada, Clindamycine-150 and Clindamycine-300 should be reported to Pro Doc Ltée or Health Canada.

If you have experienced an adverse reaction with APO-CLINDAMYCIN, please contact Apotex Drug Safety department as per the contact information below:

APOTEX INC.
150 Signet Drive
Weston, Ontario
M9L 1T9
Phone: 1-800-667-4708
Fax: 1-416-401-3819
Email: Drugsafety@apotex.com

If you have experienced an adverse reaction with CLINDAMYCINE-150 or CLINDAMYCINE-300, please contact Pro Doc Ltée as per the contact information below:

PRO DOC LTÉE
2925, Boul. Industriel
Laval, Québec
H7L 3W9
Phone: 1-800-361-8559
Fax: 1-888-977-6362
Email: medinfo@prodoc.qc.ca

You can report any suspected side effect associated with the use of health products to Health Canada by:

  • Calling toll-free at 1-866-234-2345; or
     
  • Visiting MedEffect Canada's Web page on Adverse Reaction Reporting for information on how to report online, by mail or by fax.

For other health product inquiries related to this communication, please contact Health Canada at:
Health Products and Food Branch Inspectorate Directorate
E-mail: DCVIU_UVECM@hc-sc.gc.ca
Telephone: 1-800-267-9675
Fax: 613-946-5636

Yours sincerely,

original signed by

Colin D’Cunha MBBS, MHSc, FRCPC
Director Global Medical Affairs

Marcel Lapointe, pharmacist
Director, Professional Services
Pro Doc Ltée

Warning: This Public Communication is not intended as medical advice. In order to understand the implications of this information to your health and before you modify the way you use this health product, it is important that you consult your doctor or health care professional.

Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime